DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for permanent neonatal diabetes mellitus — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePermanent neonatal diabetes mellitus maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for permanent neonatal diabetes mellitus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
insulin (INS) — INS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hc4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6TC2 · 1.36 Å · ligand 4'-HYDROXYCINNAMIC ACID (HC4). Experimental structure, not a prediction.
What the evidence adds up to
Permanent neonatal diabetes mellitus is a rare group of monogenic forms of diabetes that require insulin and present at birth or shortly after. Activating mutations in the two protein subunits of the ATP-sensitive potassium channel cause about half of all cases of permanent neonatal diabetes and some cases of transient neonatal diabetes. Identifying these mutations allows patients treated with insulin to be transferred to sulfonylureas. Other causes under study include mutations in proinsulin, FOXP3 mutations in immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, homozygous glucokinase mutations, and Wolcott-Rallinson/EIF2AK3 diabetes. Abnormalities of chromosome 6q24 remain the most common cause of transient neonatal diabetes. Recent data suggest neonatal diabetes is more common than previously thought, with variable presentations, and continued studies provide further evidence for amelioration of developmental and neurological dysfunction in a significant proportion of patients.
A 2024 case report describes a male infant with transient neonatal diabetes mellitus of unknown cause. Genetic testing excluded the majority of known mutations related to transient neonatal diabetes. The patient was treated with continuous subcutaneous insulin infusion and continuous glucose monitoring until age 2 months, when normoglycemia connected with withdrawal of treatment was noted. The report states that continuous subcutaneous insulin infusion and continuous glucose monitoring systems seem to be a safe and effective treatment option in transient neonatal diabetes and may be used in therapy.
A 2023 article on diabetes mellitus in newborns discusses genetic and autoimmune factors contributing to neonatal diabetes, clinical symptoms, genetic testing, insulin therapy, and long-term management. It advocates for proactive measures and holistic care, noting the potential impact on developmental aspects. A 1984 Spanish-language publication on transient neonatal diabetes is listed but provides no usable data.
What is still missing are large prospective studies that stratify patients by the specific genetic mutation causing their neonatal diabetes, particularly for the half of permanent cases not caused by potassium channel mutations. The long-term developmental outcomes after sulfonylurea therapy in permanent cases remain incompletely characterised, and no randomised trial has compared continuous subcutaneous insulin infusion with other insulin regimens in transient neonatal diabetes. Funding for genetic testing in all newborns with diabetes and for registries that track rare subtypes is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Endocrinology Diabetes and Obesity · 2010 · 43 citations
Update in neonatal diabetes
AbstractPURPOSE OF REVIEW: Here we give context to new data on neonatal diabetes mellitus, a rare group of insulin-requiring monogenic forms of diabetes presenting at birth or shortly thereafter. Genetic studies are critical in the diagnosis and treatment of these patients. The most common causes of neonatal diabetes are activating mutations in the two protein subunits of the ATP-sensitive potassium channel. These are responsible for about half of all cases of permanent neonatal diabetes and some cases of transient neonatal diabetes. Identification of these mutations allows patients treated with insulin to be transferred to sulfonylureas, but associated conditions and other causes must be considered. RECENT FINDINGS: Recent data suggest that neonatal diabetes is more common than previously thought, with variable presentations. Continued studies provide further evidence for amelioration of developmental and neurological dysfunction exhibited by a significant proportion of patients. Abnormalities of chromosome 6q24 remain the most common cause of transient neonatal diabetes. Other causes of neonatal diabetes being studied include mutations in proinsulin, FOXP3 mutations in immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, homozygous glucokinase mutations, and Wolcott-Rallinson/EIF2AK3 diabetes. SUMMARY: We still have much to learn about the different forms of neonatal diabetes, their associated clinical features, and the optimization of therapy using a growing number of available therapeutic agents.
Transient Neonatal Diabetes Mellitus with an Unknown Cause in a 1-Month-Old Infant: A Case Report
AbstractTransient neonatal diabetes mellitus (TNDM) is a genetically heterogeneous form of neonatal diabetes characterized by hyperglycemia that remits during infancy with a tendency to recur in later life. This case report presents the history of a male infant with transient neonatal diabetes mellitus. The patient was treated with a continuous subcutaneous insulin infusion (CSII) and a continuous glucose monitoring (CGM) system until the age of 2 months, when the normoglycemia connected with a withdrawal of treatment was noted. The genetic test results excluded the majority of known mutations related to TNDM. This case report focuses on various genetic mutations and the clinical features connected with them that cause TNDM and highlights the difficulties in the diagnostic and therapeutic processes of this disease. CSII and CGM systems seem to be a safe and effective treatment option in TNDM and may be used in the therapy.
Revista chilena de pediatría · 1984 · 0 citations · open access
Diabetes Neonatal Transitoria
AbstractAmericanae nace como un proyecto conjunto que surge dentro de la Red Europea de Información y Documentación sobre América Latina (REDIAL), y que ha afrontado la Biblioteca de la Agencia Española de Cooperación Internacional para el Desarrollo (AECID). Esta nueva biblioteca virtual hace más accesibles los libros digitales de tema americanista a los investigadores y usuarios interesados de cualquier parte del mundo.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
DIABETES MELLITUS IN NEWBORNS
AbstractThis article provides a comprehensive exploration of diabetes mellitus in newborns, delving into its causes, diagnostic methods, and treatment options. By highlighting the genetic and autoimmune factors contributing to neonatal diabetes, it offers valuable insights for medical professionals. The discussion on clinical symptoms and genetic testing aims to enhance early detection, enabling prompt intervention. Emphasizing the significance of insulin therapy and long-term management, the article addresses the complex nature of diabetes in newborns. Additionally, it underscores the potential impact on developmental aspects, advocating for proactive measures and holistic care. Overall, the article serves as an informative guide for healthcare professionals and families navigating the intricacies of diabetes mellitus in the neonatal context.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
